BioXcel Therapeutics, Inc. (BTAI)
NASDAQ: BTAI · Real-Time Price · USD
5.60
-1.20 (-17.65%)
At close: Aug 13, 2025, 4:00 PM
5.14
-0.46 (-8.21%)
Pre-market: Aug 14, 2025, 9:23 AM EDT
BioXcel Therapeutics Employees
BioXcel Therapeutics had 37 employees as of December 31, 2024. The number of employees decreased by 37 or -50.00% compared to the previous year.
Employees
37
Change (1Y)
-37
Growth (1Y)
-50.00%
Revenue / Employee
$23,459
Profits / Employee
-$1,377,027
Market Cap
33.91M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
BTAI News
- 1 day ago - BioXcel Therapeutics to Participate in the H.C. Wainwright & Co. “HCW@Home” Series - GlobeNewsWire
- 2 days ago - BioXcel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Updates - GlobeNewsWire
- 3 days ago - BioXcel Therapeutics to Participate in Canaccord Genuity 45th Annual Growth Conference - GlobeNewsWire
- 8 days ago - BioXcel Therapeutics Announces Publication in Frontiers in Pharmacology on the Effects of Dexmedetomidine (the active ingredient in BXCL-501) on Stress-Mediated Behaviors in Non-clinical Studies - GlobeNewsWire
- 13 days ago - BioXcel Therapeutics Announces Last Patient Last Visit in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia - GlobeNewsWire
- 24 days ago - BioXcel Therapeutics Submits Pre-Supplemental New Drug Application Meeting Package in Support of Potential Label Expansion for IGALMI® - GlobeNewsWire
- 6 weeks ago - BioXcel Therapeutics Receives Second Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia - GlobeNewsWire
- 2 months ago - BioXcel Therapeutics Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia - GlobeNewsWire